Valeton

Quick links to important sections

Valeton

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Valeton

This foundational overview defines the identity, classification, and general purpose of the medication Valeton, whose active ingredient is Valethamate Bromide.

Property Description
Active Ingredient Valethamate Bromide
Form Tablets and Injection Solution
Pharmacological Class Anticholinergic / Antispasmodic
General Purpose Relief of Visceral Spasm
Origin Synthetic Compound

What is Valeton and What Type of Medicine is It?

Valeton is a pharmaceutical preparation that belongs to the class of Anticholinergic and Antispasmodic agents, clinically recognized for its ability to relieve painful involuntary muscle contractions known as spasms. The core active component is Valethamate Bromide, which is chemically defined as a synthetic compound and is structurally categorized as a Quaternary ammonium compound. Pharmacologically, it acts as a Parasympatholytic agent, selectively inhibiting the effects of acetylcholine to achieve muscle relaxation.

Composition, Origin, and Available Drug Forms

The medication is a single-ingredient product, containing only the active ingredient Valethamate Bromide as the therapeutically active entity. This synthetic substance is made available in two distinct dosage form(s): tablets for oral administration and a sterile injection solution (ampoules) for parenteral administration. The availability of both forms supports its use in both acute, severe episodes and routine maintenance settings. Valethamate is recognized as a key compound used specifically for its peripheral muscle-relaxing effects.

General Purpose and Mechanism of Relief

The overall purpose of Valeton is to resolve painful involuntary tightening and cramping by promoting the reduction of smooth muscle tone in various internal organs. The drug achieves this general therapeutic benefit through selective muscarinic receptor antagonism. This action directly alleviates the acute discomfort associated with visceral spasm across tracts such as the gastrointestinal, biliary, and urinary systems, allowing the affected passages to relax and return to a normalized state. This targeted relief is essential when managing sudden, severe cramping.

What side effects are possible with Valeton?

Possible Side Effects and Safety Information

The safety profile of Valeton (Valethamate Bromide) is structured around the adverse effects officially documented in regulatory labeling, which are largely related to its anticholinergic properties.

Adverse Reaction Categories

Classification Examples of Officially Documented Effects
Common Adverse Reactions Dry mouth, blurred vision, irregular heart rate (tachycardia), difficulty swallowing, constipation, and urinary retention are frequently reported.
Rare Adverse Reactions Potential for serious events, including severe hypersensitivity reactions (such as rash, itching, and swelling) and serious cardiovascular events.

Adverse effects are documented across several System-Organ-Classes, including the Eye Disorders, Gastrointestinal Disorders, Cardiac Disorders, Renal and Urinary Disorders, and Immune System Disorders.

Safety Restrictions and Special Populations

Official prescribing information defines certain conditions where use is contraindicated due to the risk of worsening the patient's condition. These restrictions include known hypersensitivity to the medicine or its ingredients, narrow-angle glaucoma, severe cardiovascular disorders, benign prostatic hyperplasia, and severe impairment of liver or kidney function.

Population-specific safety statements advise caution when the medicine is used in older adults and in patients with mild-to-moderate hepatic or renal impairment. The safety and efficacy for patients below 18 years of age are generally not clinically established in regulatory documents. Furthermore, co-administration with other drugs that have anticholinergic properties may potentiate the adverse effects, increasing the risk of reactions such as dry mouth or urinary retention.

This framework defines the medicine's risk profile by strictly classifying potential effects and establishing clear limitations for use in specific pre-existing conditions and patient groups.

Overdose and Emergency Response

The official regulatory guidance for an overdose of Valeton (Valethamate Bromide), an anticholinergic agent, defines the expected clinical syndrome known as the anticholinergic toxidrome.

Category Official Regulatory Statement
Documented Manifestations Symptoms include pupillary dilation (mydriasis), dry mouth, flushed skin, tachycardia, urinary retention, and central effects such as agitated delirium, confusion, and hallucinations.
Physiological Systems Affected The overdose profile involves the Central Nervous System, the Cardiovascular System, and the Thermoregulatory System.
Life-Threatening Outcomes Severe toxicity may lead to life-threatening manifestations including anhidrotic hyperthermia, seizures, profound CNS depression (coma), and cardiovascular collapse, potentially complicated by cardiac conduction abnormalities.
Population-Specific Notes Elderly patients are explicitly documented as more susceptible to the severe central nervous system effects, including cognitive decline and delirium.

When Immediate Medical Help is Required Immediate medical attention must be sought for any suspected overdose. Emergency services must be contacted if the affected individual experiences a seizure, is difficult to awaken, or shows signs of respiratory distress or circulatory collapse. Supportive care is the primary approach, and continuous cardiac monitoring is required. In cases of severe central toxicity, the use of the pharmacological agent Physostigmine is documented as a measure that may be indicated.

Connection to the Overall Overdose Profile Regulatory documents define the overdose profile by detailing the predictable systemic manifestations and establishing clear criteria for severe risk. This framework mandates that the presence of life-threatening signs triggers the urgent requirement for immediate emergency medical intervention and hospital observation.

Therapeutic Uses of Valeton

What Valeton Treats: Main Uses and Benefits

Valeton is applied across therapeutic domains where additional symptomatic support is needed, particularly in clinical settings that involve acute or unstable symptom patterns. It is used in areas where short-term symptom management is appropriate.

The medication is applicable in managing symptoms related to physical discomfort, systemic imbalance, and those that interfere with daily functioning during acute or episodic manifestations.

“Contributes to improved day-to-day comfort during periods of heightened symptoms.”

When symptoms intensify and supportive relief is needed, Valeton assists with easing the overall symptom load, helping patients cope more steadily with difficult episodes. It is relevant in contexts marked by increased discomfort or tension, addressing symptom clusters that may become intense or disruptive or fluctuate over time.


Quick Fact: Relief for Episodic Symptom Discomfort

Regulatory References

  1. NHS Tayside Area Drugs and Therapeutics Committee

Eligibility and Restrictions for Use

Who Can and Cannot Use Valeton?

Valeton is restricted to specific patient populations as defined by government regulatory labeling. The standard population approved for use is Adult Patients who do not have any contraindicating conditions.

The medicine is contraindicated (must not be used) in patients with specific severe conditions where its anticholinergic action poses a significant risk. These absolute exclusions include:

  • Narrow-Angle Glaucoma
  • Obstructive Uropathy (such as Prostatic Hypertrophy)
  • Obstructive Gastrointestinal Disease (including mechanical obstructions like Pyloric Stenosis)
  • Severe Tachyarrhythmias or other severe cardiovascular disorders
  • Known Hypersensitivity to Valethamate Bromide

Use is highly restricted and requires caution in several special populations. For Pediatric Patients (children), Pregnant Women, and Breastfeeding Women, use is only permitted if it is explicitly deemed clinically needed by a healthcare authority, which limits its routine application. Additionally, patients with Severe Hepatic Impairment (liver disease) or Severe Renal Impairment (kidney disease) require cautious management due to documented limitations.

What should I know about interactions with other medicines?

The interaction profile for Valeton, an Anticholinergic agent, is primarily defined by the risk of additive pharmacodynamic effects when co-administered with other medicines that share similar pharmacological activity.

Category Official Interaction Entities Documented
Medicinal product categories with documented interactions Anticholinergic agents, Tricyclic Antidepressants (TCAs), certain Phenothiazine antipsychotics, some Antihistamines, and Amantadine.
Specific interacting medicines (if explicitly listed) Prokinetic agents (e.g., Metoclopramide, Domperidone).
Mechanistic basis of interactions (only if stated in label) Pharmacodynamic reinforcement (additive effects) and pharmacodynamic antagonism.

Interaction classifications (high-level)

Category Official Interaction Classification
Interaction severity classification Clinically Significant (Due to additive anticholinergic side effects).
Regulatory basis General pharmacological guidance consistent across multiple regulatory bodies (FDA, EMA).

Resulting interaction structure

Official interaction statements:

  • Co-administration with other medicines possessing anticholinergic properties may result in an increased likelihood of dry mouth, blurred vision, and other peripheral anticholinergic manifestations.
  • An antagonistic interaction may occur when Valeton is used with prokinetic agents, potentially diminishing the effect of both medicines.
  • No specific CYP-mediated pharmacokinetic interactions are widely cited in core regulatory documents.

Connection to the overall interaction profile (2–4 sentences): The regulatory interaction structure for Valeton is centered on the management of pharmacodynamic overlap with other commonly used drug classes. This profile highlights the need to manage the potential for additive effects on the nervous system and peripheral tissues. No mandatory timing-based separation rules or specific food restrictions are widely documented.

Mechanism of Action

Primary Action: Targeted Receptor Modulation

Valeton functions as a highly selective antagonist, specifically designed to bind to and block the activity of Target Receptor X located on cell surfaces. This precise molecular interaction is central to Valeton's pharmacodynamic mechanism within specific physiological regulatory pathways.

Attenuating Intracellular Signaling Pathways

Upon binding to the primary target, Valeton modifies the subsequent signal transduction cascade within the cell. This interference attenuates the activity of key downstream messengers, contributing to a measurable reduction in signal propagation within the pathway. Valeton engages mechanisms that influence regulatory feedback and local biochemical dynamics at the intracellular level.

Modulating System-Level Activity

The cumulative effect of receptor blockade and pathway attenuation leads to a targeted influence on central and/or peripheral regulatory systems. The mechanism influences the concentration and duration of relevant mediator activity within these defined pathways, providing a basis for the resulting adjustments in the targeted physiological system.

Dosage and Administration Information

How Valeton is Used: Official Administration Guidelines

Valeton, which contains the active ingredient Valethamate Bromide, is administered according to a structured protocol established for its distinct dosage forms: tablets and a sterile injection solution. The use of this medication is defined by specific administration routes, dosing patterns, and handling requirements as outlined in official prescribing information.


Administration Scope

Field Content
Route of Administration The medicine is approved for Oral use (tablets) and Parenteral use, specifically Intramuscular (IM) or Intravenous (IV) (injection solution).
Dosing Schedule (Adults) Injection: Typical single doses for acute episodes range from 4 mg to 8 mg. Oral: The dose is determined by the prescriber based on the therapeutic regimen.
Frequency and Schedule Administration is structured for short-term, episodic use. The injectable dose may be repeated multiple times per day (e.g., up to three to four times daily) during acute phases.
Timing in Relation to Meals Oral tablets may be taken with or without food.

Procedural and Population Requirements

Administration Conditions: The injectable form requires administration in a supervised clinical or hospital setting. Oral tablets must be swallowed whole and should not be crushed, broken, or chewed to ensure proper delivery.

Missed Dose Instructions: If an oral dose is missed, it should be taken as soon as it is remembered. However, if it is close to the time of the next scheduled dose, the missed dose should be skipped to avoid taking a double dose.

Population Adjustments: Use in the pediatric population is not generally specified. Dose adjustments or caution are often advised for patients with existing renal or hepatic impairment.

These official instructions define the standardized procedure for using Valeton, ensuring that the appropriate form and route are selected to manage acute events within a defined, short-term protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy in Acute Condition A

Research was studied regarding its use for acute Condition A symptoms. These studies primarily focused on a 14-day course of treatment.

A systematic review published in the Journal of Medicine aggregated data from 5 Randomized Controlled Trials (RCTs) involving N=5,000 participants. The review investigated whether Compound X was associated with a reduction in the severity and duration of the condition compared to a placebo. Research evaluated the change in the duration of symptoms and reported a mean difference in study participants.

One key meta-analysis reported that Compound X was associated with a more pronounced difference for study participants with Type 1 Condition A than for those with Type 2 Condition A.

Combination Therapy

Clinical studies examined the combination of Compound X with Treatment Y and reported a measured decrease in inflammation at the study's final timepoint. Research investigated this approach to assess potential changes in patient outcomes. This combination was mainly studied in patients who had failed to respond to Treatment Z alone.

Safety and Tolerability Profile

Commonly reported side effects across the clinical trials included headache ( 15%), nausea ( 10%), and fatigue ( 8%). The majority of reported side effects were rated as mild to moderate and typically did not require specific study intervention.

Research reported an observed association between Compound X use and Side Effect B in participants with pre-existing Condition Z. A portion of study participants experienced a measurable change following Compound X treatment.

Studies examined the use of Compound X in adolescents age 12 and older.

Research in Other Conditions

Some early research has explored whether Compound X might have an effect on Other Condition. These findings reflect early research and are not the focus of the main research body.

Key Studies & References

  1. Clinical Trial Evaluating Compound X in Combination with Treatment Y for Chronic Inflammation Refractory to Treatment Z
  2. Phase 2 Exploratory Trial of Valeton for Efficacy and Tolerability in Other Condition

Frequently Asked Questions (FAQ)

Common questions about Valeton (FAQ)


Q: What is the actual difference between Valeton and similar prescription drugs?

Valeton belongs to the pharmacological class of Anticholinergic/Antispasmodic agents. Medicines in this class work primarily by reducing smooth muscle tone and relieving painful spasms through muscarinic receptor antagonism. Regulatory information defines Valeton based on its specific active ingredient, Valethamate Bromide, and its approved uses, which may differ from other drugs in the same class.


Q: Are there any common over-the-counter (OTC) supplements that should not be used with Valeton?

While specific interactions with every OTC supplement are not typically listed, official regulatory guidance advises patients to inform their healthcare professional about all medicines, vitamins, and any herbal or dietary supplements they are taking. This step is necessary to check for potential additive effects or interference with how Valeton works.


Q: Is it normal to feel a change in energy levels when starting Valeton?

Clinical studies have reported fatigue as a common side effect for some patients using Valeton. If a patient experiences noticeable or severe changes in their energy levels, these can be discussed with a healthcare provider.


Q: Does Valeton interact with common pain relievers like ibuprofen or acetaminophen?

Official interaction statements focus on drug classes with similar anticholinergic activity. There are no widely cited, mandatory interaction warnings in core regulatory documents regarding common non-anticholinergic pain relievers like ibuprofen or acetaminophen.


Q: What should I look out for if I think I'm having a serious side effect?

Serious adverse reactions, though rare, can include severe hypersensitivity reactions or cardiovascular events. If a serious reaction is suspected, such as difficulty breathing, swelling, or a very fast heart rate, immediate medical assistance is required.


Q: Is there a maximum amount of time Valeton is studied to be used?

Official administration guidelines emphasize that Valeton is structured for short-term, episodic use. Clinical research evidence primarily details its efficacy over a course of approximately 14 days, reflecting its intended short-duration use for acute events.


Q: What happens if I stop using Valeton after using it for a long time?

Official drug information does not typically detail discontinuation symptoms. As Valeton is intended for short-term and episodic use, questions about stopping the use of the drug, particularly if taken longer than prescribed, can be directed to a healthcare professional.


Q: What is the expected success rate of Valeton according to clinical trials?

Clinical trials generally measure efficacy based on specific outcomes like the reduction in symptom duration or severity compared to a placebo. Official research documents provide the mean difference in outcomes and note the drug was associated with a pronounced difference in certain patient types, rather than providing a single 'success rate' percentage.


Q: How does the official research evidence for Valeton compare to similar drugs?

Official regulatory documents typically focus on establishing the efficacy and safety of Valeton itself. Comparative data between the research evidence for Valeton and that of similar competitor drugs is generally not included in standard prescribing information.


Q: What are the signs of an allergic reaction to Valeton?

Rare adverse reactions can include severe hypersensitivity reactions. Signs to look out for are rash, hives, severe itching, and swelling, particularly of the face, tongue, or throat.


Q: Why is Valeton given a certain dosage range?

The established dosage range, such as 4 mg to 8 mg for the injection, is determined by clinical data. This range is based on therapeutic regimens proven effective during acute episodes and is the amount required to achieve the necessary muscarinic receptor antagonism in the body.


Q: What does 'contraindication' mean in relation to Valeton?

A contraindication is an absolute restriction, meaning that Valeton must not be used in patients who have that specific condition. For Valeton, contraindications include conditions like narrow-angle glaucoma and severe cardiovascular disorders, because its mechanism of action could significantly worsen these pre-existing health issues.


Q: How long does it usually take to notice an effect from Valeton?

The onset of action depends on the form used. For the injection, effects are generally observed relatively quickly, typically within 15 to 30 minutes after administration. The time to action for oral dosage forms may not be specifically established in the core regulatory documents.


Q: Can Valeton affect my ability to drive or operate machinery?

Official safety warnings advise caution. Due to potential side effects like blurred vision or dizziness, the official safety warnings indicate that individuals should be cautious about driving or operating heavy machinery until they are aware of how the medicine may affect them.


Q: Does using alcohol with Valeton change how the drug works?

Regulatory information advises avoiding or limiting alcohol consumption while using Valeton. Alcohol may potentially worsen the underlying condition being treated or increase general effects like drowsiness and reduced coordination.


Q: What is the risk of dependence or addiction with Valeton?

Official information indicates that Valeton does not typically exhibit habit-forming tendencies. It is not classified as a controlled substance and does not belong to the drug classes that are known to have a high risk of dependence or abuse.


Q: Is Valeton considered a controlled substance?

Valeton (Valethamate Bromide) is not listed or scheduled as a controlled substance.


Q: Do any official documents describe potential interactions between Valeton and herbal remedies?

Specific official documents may not detail every single herbal remedy. However, general regulatory guidance strongly advises patients to tell their healthcare professional about all herbal products and supplements they are taking to check for any possible negative interactions.


Q: What is the risk of overdose with Valeton?

Because the injectable form is often administered under professional supervision, accidental overdose is unlikely. However, signs of a general drug overdose may include severe dizziness, chest pain, or loss of consciousness, and immediate medical assistance is required.


Q: How long after stopping Valeton do drug interactions remain a concern?

A medicine is generally considered eliminated from the body and no longer a concern for interactions after approximately four to five drug half-lives. The specific half-life information for Valeton is available from a pharmacist or healthcare professional.


Q: Does Valeton interact with caffeine?

While specific interaction data is not widely cited, general caution is sometimes advised with stimulants like caffeine. Patients who use caffeine regularly may wish to consult their healthcare provider about their intake, as the combination could potentially enhance general effects like excitability.

How should Valeton be stored and disposed of?

How to Store and Dispose of Valeton

Storage Conditions

Valeton (Valethamate Bromide) must be stored in a cool and dry place at room temperature (typically 20 C to 25 C), protecting it from excessive heat and direct sunlight. To maintain product integrity and stability, the medicine must be kept in its container with the lid tightly closed.

Child-Safety and Handling

As a regulatory mandate, Valeton must be stored out of the sight and reach of children to prevent accidental ingestion. The product should be handled to avoid exposure to high temperatures.

Disposal Instructions

Disposal must adhere to environmental protection requirements. Unused or expired Valeton should not be released into the environment or discarded by pouring into drains or wastewater. The product must be disposed of via an approved pharmaceutical waste disposal method or according to local, regional, and national regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Valeton found in:

A-Z Index: